This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Gastrointestinal Diseases  • Psoriasis  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Michael J. Sladden, MBChB, MAE; Philip J. Clarke, MBBS, FRACGP; John Wettenhall, MBBS, FRACP

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We read with interest the recent accounts in the Archives of paradoxical induction of psoriasislike disease in patients undergoing therapy with tumor necrosis factor (TNF-) inhibitors.^1-3 Similar reports have been published elsewhere in the dermatologic^4-5 and rheumatologic literature.^6-8

Report of a Case

We report the case of a 37-year-old woman with Crohn disease who developed palmoplantar pustulosis (PPP) during treatment with infliximab. Palmoplantar pustulosis has not previously been reported in cases of Crohn disease treated with TNF- inhibitors. Our patient was diagnosed as having Crohn disease in November 2005, had no history of psoriasis, and was otherwise healthy. A regimen of infliximab was begun at 5 mg/kg, and the patient had 3 infusions, January, June, and July 2006, resulting in complete remission of her bowel symptoms.

One month later, she developed classic PPP together with a mild psoriasiform eruption . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION